|
Beigene, Ltd. (BGNE) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
BeiGene, Ltd. (BGNE) Bundle
¡Simplifique la valoración de Beigene, Ltd. (BGNE) con esta calculadora DCF personalizable! Con Real Beigene, Ltd. (BGNE) Financials y entradas de pronóstico ajustables, puede probar escenarios y descubrir Beigene, Ltd. (BGNE) valor razonable en minutos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 428.2 | 308.9 | 1,176.3 | 1,415.9 | 2,458.8 | 3,480.1 | 4,925.7 | 6,971.8 | 9,867.9 | 13,966.9 |
| Revenue Growth, % | 0 | -27.87 | 280.83 | 20.37 | 73.65 | 41.54 | 41.54 | 41.54 | 41.54 | 41.54 |
| EBITDA | -941.3 | -1,625.9 | -1,393.2 | -1,727.4 | -1,124.6 | -3,102.5 | -4,391.2 | -6,215.2 | -8,797.0 | -12,451.2 |
| EBITDA, % | -219.81 | -526.39 | -118.44 | -122 | -45.74 | -89.15 | -89.15 | -89.15 | -89.15 | -89.15 |
| Depreciation | 18.6 | 31.8 | 46.5 | 66.3 | 87.7 | 186.8 | 264.4 | 374.2 | 529.6 | 749.6 |
| Depreciation, % | 4.35 | 10.29 | 3.95 | 4.68 | 3.57 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| EBIT | -959.9 | -1,657.7 | -1,439.7 | -1,793.7 | -1,212.3 | -3,127.3 | -4,426.3 | -6,265.0 | -8,867.4 | -12,550.8 |
| EBIT, % | -224.16 | -536.69 | -122.39 | -126.68 | -49.3 | -89.86 | -89.86 | -89.86 | -89.86 | -89.86 |
| Total Cash | 985.5 | 4,658.7 | 6,624.8 | 4,540.3 | 3,174.4 | 3,480.1 | 4,925.7 | 6,971.8 | 9,867.9 | 13,966.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 70.9 | 79.7 | 500.2 | 173.2 | 395.9 | 787.9 | 1,115.2 | 1,578.4 | 2,234.1 | 3,162.1 |
| Account Receivables, % | 16.55 | 25.79 | 42.52 | 12.23 | 16.1 | 22.64 | 22.64 | 22.64 | 22.64 | 22.64 |
| Inventories | 28.6 | 89.3 | 242.6 | 282.3 | 416.1 | 647.8 | 916.9 | 1,297.7 | 1,836.8 | 2,599.8 |
| Inventories, % | 6.67 | 28.91 | 20.63 | 19.94 | 16.92 | 18.61 | 18.61 | 18.61 | 18.61 | 18.61 |
| Accounts Payable | 122.5 | 232.0 | 168.0 | 294.8 | 315.1 | 1,055.3 | 1,493.7 | 2,114.2 | 2,992.4 | 4,235.4 |
| Accounts Payable, % | 28.6 | 75.1 | 14.29 | 20.82 | 12.82 | 30.32 | 30.32 | 30.32 | 30.32 | 30.32 |
| Capital Expenditure | -158.6 | -229.0 | -314.9 | -469.1 | -581.3 | -1,355.4 | -1,918.4 | -2,715.2 | -3,843.1 | -5,439.5 |
| Capital Expenditure, % | -37.04 | -74.15 | -26.77 | -33.13 | -23.64 | -38.95 | -38.95 | -38.95 | -38.95 | -38.95 |
| Tax Rate, % | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 |
| EBITAT | -967.0 | -1,639.6 | -1,414.4 | -1,832.8 | -1,294.3 | -3,109.5 | -4,401.1 | -6,229.3 | -8,816.9 | -12,479.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,083.9 | -1,796.9 | -2,320.6 | -1,821.6 | -2,124.1 | -4,161.5 | -6,213.1 | -8,794.0 | -12,446.9 | -17,617.2 |
| WACC, % | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -38,190.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17,970 | |||||||||
| Terminal Value | -340,104 | |||||||||
| Present Terminal Value | -239,302 | |||||||||
| Enterprise Value | -277,492 | |||||||||
| Net Debt | -2,242 | |||||||||
| Equity Value | -275,250 | |||||||||
| Diluted Shares Outstanding, MM | 104 | |||||||||
| Equity Value Per Share | -2,636.82 |
What You Will Receive
- Comprehensive Financial Model: BeiGene’s actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Instant updates provide immediate insights as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation needs.
- Flexible and Reusable: Designed for adaptability, enabling multiple uses for in-depth forecasts.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for BeiGene, Ltd. (BGNE).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs for accurate assessments.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for BeiGene, Ltd. (BGNE).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- Download: Obtain the pre-built Excel file featuring BeiGene, Ltd.'s (BGNE) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose BeiGene, Ltd. (BGNE)?
- Innovative Solutions: Access cutting-edge therapies designed to transform patient care.
- Commitment to Quality: Rigorous research and development ensure high standards in every product.
- Global Reach: Benefit from a worldwide network that enhances collaboration and distribution.
- Patient-Centric Approach: Focused on addressing unmet medical needs and improving outcomes.
- Expertise You Can Trust: Backed by a team of seasoned professionals dedicated to excellence.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world case studies.
- Researchers: Integrate cutting-edge models into academic projects or scientific studies.
- Investors: Evaluate your investment strategies and assess valuation metrics for BeiGene, Ltd. (BGNE).
- Market Analysts: Enhance your analysis capabilities with a customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Learn how large biotech companies like BeiGene, Ltd. (BGNE) are assessed and valued in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled BeiGene historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for BeiGene, Ltd. (BGNE).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.